MatthewPBoenteMD

Obstetrics & Gynecology • Edina, MN

General Gynecology, Gynecologic Oncology

Medical Director, US Medical Affairs Gynecologic Oncology Genentech BioOncology

Join to view full profile

Dr. Boente is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Boente's full profile

Already have an account?

Office
6545 France Ave S
Ste 210
Edina, MN 55435
Phone+1 952-928-2900

Fax+1 952-928-2944

Education & Training

Rush University Medical CenterResidency, Obstetrics and Gynecology, 1986 - 1990
Rush Medical College of Rush University Medical CenterClass of 1986
Duke University HospitalFellowship, Gynecologic Oncology

Certifications & Licensure

FL State Medical License 2017 - 2019
MN State Medical License 2001 - 2018

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Top MD Consumers Checkbook
Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

Clinical Trials

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
Active, not recruiting
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Start of enrollment: 2012 Jun 18
Completed
Phase 3
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Start of enrollment: 2014 Feb 14
Terminated
Phase 2
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
Lari Wenzel, Helen Q. Huang, David Cella, Chelsea O. McKinney, Michael A. Zevon
Gynecologic Oncology. 2021-09-20
25 citations
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley
Clinical Cancer Research. 2020-03-15
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B Sibley
Clinical cancer research : an official journal of the American Association for Cancer Research. 2020-01-11

Professional Memberships

American College of Obstetricians and Gynecologists
Fellow
American College of Surgeons - ACS
Member